Target intelligence / Profile preview

SNCA antisense RNA 1 (SNCA-AS1)

Target
SNCA-AS1
Molecular classification
Long non-coding RNA (lncRNA), Non-coding RNA, Other
01

Overview

SNCA antisense RNA 1 (SNCA-AS1) is a long non-coding RNA transcribed from the opposite strand of the SNCA gene locus, with partial overlap of the 5' exonic region of SNCA. SNCA-AS1 regulates the expression of SNCA, which encodes α-synuclein, a key protein involved in synaptic function and whose pathological aggregation is a hallmark of Parkinson’s disease and related disorders. Overexpression of SNCA-AS1 leads to increased SNCA expression and promotes changes in the transcriptome associated with reduced synaptic plasticity, altered neurite extension, and increased cellular senescence — processes central to brain aging and neurodegeneration. Reduced SNCA-AS1 has the opposite effect, decreasing SNCA levels and related pathogenic pathways. SNCA-AS1 is thus both a molecular regulator of synaptic and aging biology and a promising target for disease-modifying approaches in neurodegenerative disease, especially Parkinson's disease.

Other names
SNCA antisense RNA 1SNCA-AS1Alpha-synuclein antisense transcript
02

Mechanism of action

Inhibition of SNCA-AS1 expression can lead to downregulation of SNCA (reducing α-synuclein production). Overexpression of SNCA-AS1 increases SNCA mRNA and protein, promoting pathogenic processes associated with Parkinson’s disease. Antisense oligonucleotides (ASOs) may block SNCA-AS1 or its effects on the sense SNCA transcript.

03

Biological functions

Regulation of SNCA (alpha-synuclein) gene expressionSynaptogenesis and synaptic plasticityRegulation of neurite extensionModulation of cellular senescenceModulation of gene expression in dopaminergic and GABAergic synapses
04

Disease associations

Neurodegenerative disease (notably Parkinson’s disease and related synucleinopathies)Aging-related diseases
05

Safety considerations

Potential off-target gene regulation due to the broad influence of lncRNAs on transcriptional networks.The possible impact of altering SNCA-AS1 on normal synaptic biology and neuronal function, given its role in synaptogenesis.Long-term effects of lncRNA-targeted therapies are not fully understood.
06

Interacting drugs

antisense oligonucleotides (ASOs)
07

Biomarkers

Expression levels of SNCA-AS1 in neural tissue or cellsExpression levels of SNCA mRNA or α-synuclein protein as downstream indicators

Beyond the preview

Go deeper on SNCA antisense RNA 1 (SNCA-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNCA antisense RNA 1 (SNCA-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call